Mesenchymal stromal cells to treat patients with non‐ischaemic heart failure: Results from SCIENCE II pilot study

Aims Allogeneic stem cell therapy is more logistically suitable compared with autologous cell therapy for large‐scale patient treatment. We aim to investigate the clinical safety and efficacy profile of the allogeneic adipose tissue derived mesenchymal stromal cell product (CSCC_ASC) as an add‐on therapy in patients with chronic non‐ischaemic heart failure with reduced left ventricular ejection fraction (HFrEF) 300 pg/mL (>35 pmol/L) were included and randomized 2:1 to CSCC_ASC or standard care. The primary endpoint left ventricular end systolic volume (LVESV) and other echo related parameters were analysed by an investigator blinded for treatment allocation. No difference in serious adverse events was observed between groups. LVESV decreased significantly from baseline to 6 months follow‐up in the ASC group (153.7 ± 53.2 mL and 128.7 ± 45.6 mL, P